ITM Set to Present Phase 3 COMPETE Trial Post Hoc Subgroup Analyses and Conduct Satellite Symposium at NANETS 2025

Garching / Munich, Germany, October 17, 2025 – , a prominent radiopharmaceutical biotechnology firm, today disclosed that post hoc subgroup analyses data from its will be featured in an oral presentation at the 2025 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium, taking place from October 22–25, 2025, in Austin, Texas. The company will also operate a medical exhibit (booth number: 16) at the conference and will host a satellite symposium dedicated to advancing targeted therapies and molecular imaging for gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Information on Oral Presentation
Topic: Efficacy of ¹⁷⁷Lu-edotreotide vs Everolimus in patients with Grade 1 or Grade 2 GEP-NETs: Phase 3 COMPETE trial (post hoc subgroup analyses)
Session: Featured Abstracts 2: Advancing Targeted Therapies and Molecular Imaging in GEP-NETs
Date and Time: Friday, October 24, 2025, from 3:35 pm – 4:50 pm CDT
Venue: JW Marriott Austin
Presenter: Jaume Capdevila, MD, PhD, a study investigator and senior medical oncologist at Vall d’Hebron University Hospital, Barcelona

Details of Satellite Symposium
Theme: What’s Your Next Move? Sequencing Therapies in GEP-NETs
Date and Time: Friday, October 24, 2025, from 7:00 am – 8:00 am CDT
Venue: JW Marriott Austin, Lone Star Salon E-H
Moderator: Namrata Vijayvergia, MD, Section Chief, Gastrointestinal Medical Oncology; Associate Professor, Department of Hematology/Oncology; Medical Director, Medical Oncology, Fox Chase Cancer Center
Panelists: Jaume Capdevila, MD, PhD, study investigator and senior medical oncologist at Vall d’Hebron University Hospital; Jessica Maxwell, MD, MBA, Assistant Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center; Jonathan Strosberg, MD, Professor, Moffitt Cancer Center; Harshad Kulkarni, MD, Chief Medical Advisor, BAMF Health

About the COMPETE Study
The COMPETE trial (NCT03049189) investigated ¹⁷⁷Lu-edotreotide (ITM-11), a proprietary, synthetic, targeted radiotherapeutic investigational agent, in comparison to everolimus, a targeted molecular therapy. This investigation involved patients diagnosed with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The trial successfully achieved its primary endpoint, with ¹⁷⁷Lu-edotreotide exhibiting a clinically and statistically significant improvement in progression-free survival (PFS) when compared to everolimus. ¹⁷⁷Lu-edotreotide is additionally being assessed in COMPOSE, a Phase 3 study for patients with well-differentiated, aggressive Grade 2 or Grade 3, SSTR-positive GEP-NET tumors.

About ITM Isotope Technologies Munich SE
ITM, a leading radiopharmaceutical biotech company, is committed to delivering a new generation of radiopharmaceutical treatments and diagnostics for cancers that are challenging to treat. Our objective is to address the requirements of cancer patients, clinicians, and our partners through excellence in the development, production, and global distribution of medical radioisotopes. With enhanced patient benefit as the guiding principle for all our efforts, ITM is advancing a broad precision oncology pipeline, which includes multiple Phase 3 studies, by combining the company’s high-quality radioisotopes with a diverse range of targeting molecules. Leveraging our two decades of pioneering radiopharma expertise, central industry standing, and established global network, ITM aims to provide patients with more effective targeted therapies to improve clinical results and quality of life. 

ITM Contact Information
Corporate Communications
Kathleen Noonan/Julia Westermeir
Phone: +49 89 329 8986 1500
Email:

Investor Relations
Ben Orzelek
Phone: +49 89 329 8986 1009
Email:

Attachment